Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Portal hypertension is a lethal complication of cirrhosis. Its mechanism and therapeutic targets remain largely unknown. Hepatic stellate cell (HSC) contraction increases intrahepatic vascular resistance contributing to portal hypertension. We investigated how HSC contraction was regulated by Wnt signaling and the therapeutic implication.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>Liver tissues from cirrhotic patients were examined. Cirrhotic mice with genetic or pharmacological treatments were used for <i>in vivo</i> assessments and their primary cells were isolated. Cellular functions and signaling pathways were analyzed in human HSC‐LX2 cells using real‐time PCR, Western blotting, siRNA, luciferase reporter assay, chromatin immunoprecipitation, co‐immunoprecipitation, and site‐directed mutagenesis. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>Wnt/β‐catenin correlated with HSC contraction in human cirrhotic liver. Wnt3a stimulated Smo‐independent Gli1 nuclear translocation followed by LARG‐mediated RhoA activation leading to HSC contraction. Sufu negatively mediated Wnt3a‐induced Gli1 nuclear translocation. Wnt/β‐catenin repressed the transcription of Sufu dependent on β‐catenin/TCF4 interaction and TCF4 binding to Sufu promoter. Molecular simulation and site‐directed mutagenesis identified the β‐catenin residues Lys312 and Lys435 critically involved in the interaction. Additionally, TCF4 binding to the sequence CACACCTTCC at Sufu promoter was required for transrepression of Sufu. In cirrhotic mice, short‐term liver‐targeting β‐catenin deficiency or acute treatment with β‐catenin inhibitors reduced portal pressure via restriction of HSC contraction rather than inhibition of HSC activation. Long‐term deficiency or treatments also ameliorated liver injury, fibrosis and inflammation.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions and Implications</h3><p>Interaction between Wnt/β‐catenin and Smo‐independent Gli1 pathways promoted HSC contraction via TCF4‐dependent transrepression of Sufu. HSC‐specific inhibition of β‐catenin may have therapeutic benefits for cirrhotic portal hypertension.</p></section>

Regulation of hepatic stellate cell contraction and cirrhotic portal hypertension by Wnt/β‐catenin signalling via interaction with Gli1

PLK1 regulates hepatic stellate cell activation and liver fibrosis through Wnt/-catenin signalling pathway

Circular RNA Circube2k Promotes Hepatic Fibrosis Via Sponging Mir‐149‐5p/tgf‐β2 Axis

Wnt5a Promotes Cytokines Production and Cell Proliferation in Human Hepatic Stellate Cells Independent of Canonical Wnt Pathway.

β-catenin is overexpressed in hepatic fibrosis and blockage of Wnt/β-catenin signaling inhibits hepatic stellate cell activation.

Single‐Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell–Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice

CAT1 Silencing Inhibits TGF-β1-induced Mouse Hepatic Stellate Cell Activation in Vitro and Hepatic Fibrosis in Vivo.

Autocrine CTHRC1 activates hepatic stellate cells and promotes liver fibrosis by activating TGF-β signaling

Histone methyltransferase Suv39h1 regulates hepatic stellate cell activation and is targetable in liver fibrosis

The mechanical mechanism of angiotensin II induced activation of hepatic stellate cells promoting portal hypertension

Wnt signaling in liver fibrosis: progress, challenges and potential directions

An HNF1α-regulated Feedback Circuit Modulates Hepatic Fibrogenesis Via the Crosstalk Between Hepatocytes and Hepatic Stellate Cells.

An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis

MicroRNA-214 Promotes Hepatic Stellate Cell Activation and Liver Fibrosis by Suppressing Sufu Expression

Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1α transcriptional complex

ZEB1 Regulates the Activation of Hepatic Stellate Cells Through Wnt/β-catenin Signaling Pathway

Experimental study of activation of mtor/p70s6k signaling pathway in liver cirrhotic portal hypertension

Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies

Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo

The HLF/IL-6/STAT3 Feedforward Circuit Drives Hepatic Stellate Cell Activation to Promote Liver Fibrosis

Targeting Follistatin like 1 ameliorates liver fibrosis induced by carbon tetrachloride through TGF-β1-miR29a in mice